UNSPSC 51102845: Hydrocortisone/neomycin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.

UNSPSC 51102845 Hydrocortisone/neomycin is a Commodity code for a specific pharmaceutical product combination, yet the recent state and local solicitations tagged under it do not reflect procurement of hydrocortisone/neomycin itself. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets—both antibiotics unrelated to the code's nominal scope. Seminole County, Florida issued an IFB in June 2026 for Naloxone and Safe Drug Deactivation Systems, also outside the hydrocortisone/neomycin product category. The code shows little relevant recent activity aligned with its stated pharmaceutical product.

Activity under this code involves state health departments and county health systems as primary issuing bodies, with procurement structured through piggyback cooperative purchasing agreements and competitive IFB processes. The two recent opportunities span Florida and Illinois. The Illinois award to Chartwell Rx LLC represented $2,999,999.11 over a three-year term including renewal options, while the Seminole County IFB sought 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building. Neither solicitation aligns with the code's intended product category, suggesting the code may be misapplied to broader pharmaceutical procurement or that state and local cataloging practices have diverged from UNSPSC intent.